CareLit Fachartikel

FAPI PET/CT provides higher uptake and better target to back ground in recurrent and metastatic tumors of patients with Iodine refractory papillary thyroid cancer compared with FD…

Shaghayegh Nourbakhsh, Yalda Salehi, Saeed Farzanehfar, Reza Ghaletaki, Mohsen Bakhshi Kashi, Mehrshad Abbasi · Nuklearmedizin - NuclearMedicine · 2025 · Heft 03 · S. 188-192

Dokument
976731
CareLit-ID
Jahr
2025
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Nuklearmedizin - NuclearMedicine
Autor:innen
Shaghayegh Nourbakhsh, Yalda Salehi, Saeed Farzanehfar, Reza Ghaletaki, Mohsen Bakhshi Kashi, Mehrshad Abbasi
Ausgabe
Heft 03 / 2025
Jahrgang 64
Seiten
188-192
Erschienen: 2025-06-01 00:00:00
ISSN
0029-5566

Zusammenfassung

Abstract Purpose The role of fibroblast activation protein inhibitor (FAPI) PET CT scan is not well documented in papillary thyroid cancer (PTC) patients. Patients with radioiodine refractory PTC and high thyroglobulin levels need PET/CT scan which is generally done by 18F FDG. In the current study, the diagnostic performance of 68Ga FAPI and FDG PET/CT scans were compared head to head in patients with radioiodine refractory PTC. Method Fourteen patients with negative whole body Iodine scans and high thyroglobulin levels underwent whole body PET scans with, respectively, 120–310 and 145–370 MBq 68Ga FAPI-46 and…

Schlagworte

papillary thyroid cancer radioiodine PET CT scan Fibroblast activation protein Nuklearmedizin - NuclearMedicine